FDA removes clinical hold on Aardvark Therapeutics' ARD-101 for Prader-Willi syndrome

The FDA removed the clinical hold on Aardvark Therapeutics' investigational new drug application for ARD-101, being developed to treat hyperphagia in Prader-Willi syndrome.

Detected & updated continuously · Source: Nebula